creatine has been researched along with Renal Insufficiency, Chronic in 38 studies
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Proteinuria was observed in 27% of 153 patients taking tenofovir for more than 1 year." | 7.79 | Tenofovir-associated proteinuria. ( Bartlett, H; Gibson, A; Kelly, MD; Patten, J; Rowling, D, 2013) |
| "We found that Cordyceps preparation, as an adjuvant therapy to conventional medicine, showed potential promise to decrease serum creatinine, increase creatine clearance, reduce proteinuria and alleviate CKD-associated complications, such as increased haemoglobin and serum albumin." | 4.90 | Cordyceps sinensis (a traditional Chinese medicine) for treating chronic kidney disease. ( Chan, LS; Kwan, TH; Leung, C; Lin, ZX; Mok, CK; Tung, YS; Zhang, HW, 2014) |
| "Creatine is an essential contributor to cellular energy homeostasis, yet, on a daily basis, 1." | 4.11 | Chronic Dialysis Patients Are Depleted of Creatine: Review and Rationale for Intradialytic Creatine Supplementation. ( Appeldoorn, TYJ; Bakker, SJL; Franssen, CFM; Heiner-Fokkema, MR; Koops, CA; Kremer, D; Marsman, E; Post, A; Touw, DJ; van der Veen, Y; Wallimann, T; Westerhuis, R, 2021) |
| "Proteinuria was observed in 27% of 153 patients taking tenofovir for more than 1 year." | 3.79 | Tenofovir-associated proteinuria. ( Bartlett, H; Gibson, A; Kelly, MD; Patten, J; Rowling, D, 2013) |
| "Patients with chronic kidney disease and type 2 diabetes have a higher risk of developing pneumonia as well as an increased risk of severe COVID-19-associated adverse events and mortality." | 3.11 | Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis. ( Agarwal, R; Ahlers, C; Anker, SD; Brinker, M; Filippatos, GS; Joseph, A; Lambelet, M; Lawatscheck, R; Pitt, B; Rossing, P; Ruilope, LM, 2022) |
| "Creatine is an essential contributor in cellular energy homeostasis, yet on a daily basis 1." | 2.61 | Creatine is a Conditionally Essential Nutrient in Chronic Kidney Disease: A Hypothesis and Narrative Literature Review. ( Bakker, SJL; Post, A; Tsikas, D, 2019) |
| " Risedronate was safe and effective in osteoporotic women with mild, moderate, or severe age-related renal impairment." | 2.43 | Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. ( Barton, IP; Boonen, S; Burgio, DE; Dunlap, LE; Miller, PD; Roux, C, 2005) |
| "Vascular calcification is a risk factor for causing cardiovascular events and has a high prevalence among chronic kidney disease (CKD) patients." | 1.42 | High phosphorus level leads to aortic calcification via β-catenin in chronic kidney disease. ( Fan, X; Feng, JM; Liu, LL; Ma, JF; Ren, C; Sun, L; Sun, W; Sun, YT; Wang, LN; Xu, TH; Yao, L, 2015) |
| "Asymmetric dimethylarginine (ADMA) has been suggested as a possible marker of endothelial dysfunction, and interest in its use in clinical practice is increasing." | 1.36 | HPLC determination of plasma dimethylarginines: method validation and preliminary clinical application. ( Artusi, C; Boffa, GM; Ivanova, M; Plebani, M; Zaninotto, M, 2010) |
| "Creatine is an amino acid which is a precursor of creatinine, and is known to transiently increase serum creatinine." | 1.34 | How we estimate GFR--a pitfall of using a serum creatinine-based formula. ( Kanagasundaram, NS; Moochhala, SH; Refaie, R, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (7.89) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (5.26) | 29.6817 |
| 2010's | 23 (60.53) | 24.3611 |
| 2020's | 10 (26.32) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, Y | 1 |
| Silver, SM | 1 |
| Sterns, RH | 1 |
| Chen, SJ | 1 |
| Tseng, CC | 1 |
| Huang, KH | 1 |
| Chang, YC | 1 |
| Fu, LM | 1 |
| Khattri, RB | 1 |
| Kim, K | 1 |
| Anderson, EM | 1 |
| Fazzone, B | 1 |
| Harland, KC | 1 |
| Hu, Q | 1 |
| Palzkill, VR | 1 |
| Cort, TA | 1 |
| O'Malley, KA | 1 |
| Berceli, SA | 1 |
| Scali, ST | 1 |
| Ryan, TE | 1 |
| Xu, LY | 1 |
| Hui, M | 1 |
| Zhu, SH | 1 |
| Yang, Z | 1 |
| Li, MR | 1 |
| Yang, HY | 1 |
| Zheng, XZ | 1 |
| Lv, JC | 1 |
| Yang, L | 1 |
| Pitt, B | 1 |
| Agarwal, R | 1 |
| Anker, SD | 1 |
| Ruilope, LM | 1 |
| Rossing, P | 1 |
| Ahlers, C | 1 |
| Brinker, M | 1 |
| Joseph, A | 1 |
| Lambelet, M | 1 |
| Lawatscheck, R | 1 |
| Filippatos, GS | 1 |
| Ding, K | 1 |
| Li, Z | 1 |
| Lu, Y | 1 |
| Sun, L | 2 |
| Ochiai, H | 1 |
| Shirasawa, T | 1 |
| Yoshimoto, T | 1 |
| Nagahama, S | 1 |
| Watanabe, A | 1 |
| Sakamoto, K | 1 |
| Kokaze, A | 1 |
| Saud, A | 1 |
| Luiz, RS | 1 |
| Leite, APO | 1 |
| Muller, CR | 1 |
| Visona, I | 1 |
| Reinecke, N | 1 |
| Silva, WH | 1 |
| Gloria, MA | 1 |
| Razvickas, CV | 1 |
| Casarini, DE | 1 |
| Schor, N | 1 |
| Hashimoto, T | 1 |
| Shibata, K | 1 |
| Honda, K | 1 |
| Nobe, K | 1 |
| van der Veen, Y | 1 |
| Post, A | 2 |
| Kremer, D | 1 |
| Koops, CA | 1 |
| Marsman, E | 1 |
| Appeldoorn, TYJ | 1 |
| Touw, DJ | 1 |
| Westerhuis, R | 1 |
| Heiner-Fokkema, MR | 1 |
| Franssen, CFM | 1 |
| Wallimann, T | 1 |
| Bakker, SJL | 2 |
| Nash, DM | 1 |
| Garg, AX | 1 |
| Brimble, KS | 1 |
| Markle-Reid, M | 1 |
| Medrano Navarro, AL | 1 |
| Justel Enríquez, A | 1 |
| Alameda Serrano, J | 1 |
| Blasco Lamarca, Y | 1 |
| Sáenz Abad, D | 1 |
| Gimeno Orna, JA | 1 |
| Tsikas, D | 1 |
| Lopes, MB | 1 |
| Araújo, LQ | 1 |
| Passos, MT | 1 |
| Nishida, SK | 1 |
| Kirsztajn, GM | 1 |
| Cendoroglo, MS | 1 |
| Sesso, RC | 1 |
| Lin, YC | 1 |
| Bansal, N | 1 |
| Vittinghoff, E | 1 |
| Go, AS | 1 |
| Hsu, CY | 1 |
| Nagai, K | 1 |
| Doi, T | 1 |
| Rayane, R | 1 |
| Yu, B | 1 |
| Zheng, Y | 1 |
| Nettleton, JA | 1 |
| Alexander, D | 1 |
| Coresh, J | 1 |
| Boerwinkle, E | 1 |
| Koo, HS | 1 |
| Kim, YC | 1 |
| Ahn, SY | 2 |
| Oh, SW | 1 |
| Kim, S | 3 |
| Chin, HJ | 2 |
| Kim, DK | 1 |
| Park, JH | 1 |
| Shin, SJ | 1 |
| Lee, SH | 1 |
| Choi, BS | 1 |
| Lim, CS | 1 |
| Stack, AG | 1 |
| Casserly, LF | 1 |
| Cronin, CJ | 1 |
| Chernenko, T | 1 |
| Cullen, W | 1 |
| Hannigan, A | 1 |
| Saran, R | 1 |
| Johnson, H | 1 |
| Browne, G | 1 |
| Ferguson, JP | 1 |
| Chase, HS | 1 |
| Hirsch, JS | 1 |
| Mohan, S | 1 |
| Rao, MK | 1 |
| Radhakrishnan, J | 1 |
| Zhang, HW | 1 |
| Lin, ZX | 1 |
| Tung, YS | 1 |
| Kwan, TH | 1 |
| Mok, CK | 1 |
| Leung, C | 1 |
| Chan, LS | 1 |
| Yao, L | 1 |
| Sun, YT | 1 |
| Sun, W | 1 |
| Xu, TH | 1 |
| Ren, C | 1 |
| Fan, X | 1 |
| Liu, LL | 1 |
| Feng, JM | 1 |
| Ma, JF | 1 |
| Wang, LN | 1 |
| Benito, S | 1 |
| Sánchez, A | 1 |
| Unceta, N | 1 |
| Andrade, F | 1 |
| Aldámiz-Echevarria, L | 1 |
| Goicolea, MA | 1 |
| Barrio, RJ | 1 |
| Norouzi, J | 1 |
| Yadollahpour, A | 1 |
| Mirbagheri, SA | 1 |
| Mazdeh, MM | 1 |
| Hosseini, SA | 1 |
| Neild, GH | 1 |
| Park, JI | 1 |
| Baek, H | 1 |
| Jung, HH | 1 |
| Ivanova, M | 1 |
| Artusi, C | 1 |
| Boffa, GM | 1 |
| Zaninotto, M | 1 |
| Plebani, M | 1 |
| Kelly, MD | 1 |
| Gibson, A | 1 |
| Bartlett, H | 1 |
| Rowling, D | 1 |
| Patten, J | 1 |
| Shafat, I | 1 |
| Agbaria, A | 1 |
| Boaz, M | 1 |
| Schwartz, D | 1 |
| Baruch, R | 1 |
| Nakash, R | 1 |
| Ilan, N | 1 |
| Vlodavsky, I | 1 |
| Weinstein, T | 1 |
| Imamura, T | 1 |
| Kinugawa, K | 1 |
| Shiga, T | 1 |
| Kato, N | 1 |
| Muraoka, H | 1 |
| Minatsuki, S | 1 |
| Inaba, T | 1 |
| Maki, H | 1 |
| Hatano, M | 1 |
| Yao, A | 1 |
| Kyo, S | 1 |
| Nagai, R | 1 |
| McIntyre, NJ | 1 |
| Fluck, RJ | 1 |
| McIntyre, CW | 1 |
| Fakis, A | 1 |
| Taal, MW | 1 |
| TOBIAS, GJ | 1 |
| McLAUGHLIN, RF | 1 |
| HOPPER, J | 1 |
| TOIVANEN, P | 1 |
| SAARIMAA, HA | 1 |
| FONKEN, HA | 1 |
| ELLIS, PP | 1 |
| Miller, PD | 1 |
| Roux, C | 1 |
| Boonen, S | 1 |
| Barton, IP | 1 |
| Dunlap, LE | 1 |
| Burgio, DE | 1 |
| Refaie, R | 1 |
| Moochhala, SH | 1 |
| Kanagasundaram, NS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate the Safety and Efficacy of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Subjects With Type 2 Dia[NCT02540993] | Phase 3 | 5,734 participants (Actual) | Interventional | 2015-09-17 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate Efficacy and Safety of Finerenone on the Reduction of Cardiovascular Morbidity and Mortality in Subjects With Type 2 Diabetes Mellitus a[NCT02545049] | Phase 3 | 7,352 participants (Actual) | Interventional | 2015-09-17 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Count of participants and time from randomization to the first occurrence of a hospitalization event were evaluated. Number of participants with the event is reported as descriptive result and hazard ratio is reported as statistical analysis. (NCT02540993)
Timeframe: From randomization up until the first occurrence of the hospitalization due to any cause, or censoring at the end of study, with an average of 32 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 1263 |
| Placebo | 1321 |
Count of participants and time from randomization until death due to any cause were evaluated. Number of participants with outcome death is reported as descriptive result and hazard ratio is reported as statistical analysis. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table. (NCT02540993)
Timeframe: From randomization up until death due to any cause, or censoring at the end of the study visit, with an average of 32 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 219 |
| Placebo | 244 |
First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the participant was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change. (NCT02540993)
Timeframe: From baseline up until Month 4
| Intervention | Ratio (Least Squares Mean) |
|---|---|
| Finerenone | 0.655 |
| Placebo | 0.952 |
Count of participants and time from randomization to the first occurrence of the key secondary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis. (NCT02540993)
Timeframe: From randomization up until the first occurrence of the key secondary CV composite endpoint, or censoring at the end of the study, with an average of 32 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 367 |
| Placebo | 420 |
Count of participants and time from randomization to the first occurrence of the secondary renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of ≥57% from baseline over at least 4 weeks, or renal death were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis. (NCT02540993)
Timeframe: From randomization up until the first occurrence of the composite primary endpoint, or censoring at the end of the study, with an average of 32 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 252 |
| Placebo | 326 |
Count of participants and time from randomization to the first occurrence of the primary renal composite outcome, onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis. (NCT02540993)
Timeframe: From randomization up until the first occurrence of the primary renal composite endpoint, or censoring at the end of the study, with an average follow-up time of 32 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 504 |
| Placebo | 600 |
Number of participants with first occurrence of a hospitalization event were reported as descriptive result. (NCT02545049)
Timeframe: From randomization up until the first occurrence of the hospitalization due to any cause, or censoring at the end of study, with an average study duration of 41 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 1573 |
| Placebo | 1605 |
Number of participants with death due to any cause were reported as descriptive result. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table. (NCT02545049)
Timeframe: From randomization up until death due to any cause, or censoring at the end of the study, with an average study duration of 41 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 333 |
| Placebo | 370 |
First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the participant was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change. (NCT02545049)
Timeframe: From baseline up until Month 4
| Intervention | Ratio (Least Squares Mean) |
|---|---|
| Finerenone | 0.624 |
| Placebo | 0.922 |
Number of participants with the first occurrence of the primary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were reported as descriptive result. (NCT02545049)
Timeframe: From randomization up until the first occurrence of the CV composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 458 |
| Placebo | 519 |
Number of participants with first occurrence of the renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of ≥57% from baseline over at least 4 weeks, or renal death were reported as descriptive result. (NCT02545049)
Timeframe: From randomization up until the first occurrence of the renal composite endpoint, or censoring at the end of the study, with an average study duration of 41 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 108 |
| Placebo | 139 |
Number of participants with first occurrence of the composite endpoint of onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death were reported as descriptive result. (NCT02545049)
Timeframe: From randomization up until the first occurrence of the renal composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 350 |
| Placebo | 395 |
7 reviews available for creatine and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Estimating urine volume from the urine creatinine concentration.
Topics: Aged; Creatine; Creatinine; Glomerular Filtration Rate; Humans; Kidney Function Tests; Obesity, Morb | 2023 |
Chronic Dialysis Patients Are Depleted of Creatine: Review and Rationale for Intradialytic Creatine Supplementation.
Topics: Creatine; Dietary Supplements; Double-Blind Method; Health Status; Humans; Netherlands; Pilot Projec | 2021 |
Creatine is a Conditionally Essential Nutrient in Chronic Kidney Disease: A Hypothesis and Narrative Literature Review.
Topics: Creatine; Diet; Humans; Nutrients; Renal Insufficiency, Chronic | 2019 |
[New era of laboratory testing. Topics: II. Particulars; 3. Laboratory examination for the diagnosis of CKD or AKI].
Topics: Acute Kidney Injury; Biomarkers; Creatine; Cystatin C; Diagnostic Techniques, Urological; Humans; Re | 2013 |
Cordyceps sinensis (a traditional Chinese medicine) for treating chronic kidney disease.
Topics: Cordyceps; Creatine; Creatinine; Humans; Phytotherapy; Proteinuria; Randomized Controlled Trials as | 2014 |
Life expectancy with chronic kidney disease: an educational review.
Topics: Adolescent; Adult; Age Factors; Cardiovascular Diseases; Child; Creatine; Female; Glomerular Filtrat | 2017 |
Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
Topics: Age Factors; Aged; Aged, 80 and over; Algorithms; Bone Density; Bone Density Conservation Agents; Bo | 2005 |
3 trials available for creatine and Renal Insufficiency, Chronic
29 other studies available for creatine and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Microfluidic Sliding Paper-Based Device for Point-of-Care Determination of Albumin-to-Creatine Ratio in Human Urine.
Topics: Albumins; Creatine; Creatinine; Humans; Microfluidics; Point-of-Care Systems; Renal Insufficiency, C | 2022 |
Metabolomic profiling reveals muscle metabolic changes following iliac arteriovenous fistula creation in mice.
Topics: Adenine; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Arteriovenous Fistula; Arterioven | 2022 |
[Chronic kidney disease in community: Current state for screening and management].
Topics: Albuminuria; Blood Glucose; Creatine; Glomerular Filtration Rate; Humans; Renal Insufficiency, Chron | 2022 |
Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease.
Topics: Bayes Theorem; Cardiovascular Diseases; Creatine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; | 2023 |
Elevated alanine aminotransferase and low aspartate aminotransferase/alanine aminotransferase ratio are associated with chronic kidney disease among middle-aged women: a cross-sectional study.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Creatine; Cross-Sectional Studies; Female; gamma- | 2020 |
Resistance exercise training ameliorates chronic kidney disease outcomes in a 5/6 nephrectomy model.
Topics: Animals; Creatine; Disease Models, Animal; Male; Nephrectomy; Rats; Rats, Wistar; Renal Insufficienc | 2021 |
Acetic acid treatment causes renal inflammation and chronic kidney disease in mice.
Topics: Acetic Acid; Animals; Creatine; Disease Models, Animal; Gene Expression; Interleukin-1beta; Kidney; | 2021 |
Primary care provider perceptions of enablers and barriers to following guideline-recommended laboratory tests to confirm chronic kidney disease: a qualitative descriptive study.
Topics: Adult; Biomarkers; Creatine; Decision Making; Female; Guideline Adherence; Health Knowledge, Attitud | 2018 |
Total and cardiovascular mortality risk according to KDIGO guidelines classification in type 2 diabetic patients.
Topics: Adult; Albuminuria; Analysis of Variance; Cardiovascular Diseases; Cause of Death; Chi-Square Distri | 2019 |
Estimation of glomerular filtration rate from serum creatinine and cystatin C in octogenarians and nonagenarians.
Topics: Aged, 80 and over; Algorithms; Biomarkers; Brazil; Creatine; Cystatin C; Diagnosis, Computer-Assiste | 2013 |
Determinants of the creatinine clearance to glomerular filtration rate ratio in patients with chronic kidney disease: a cross-sectional study.
Topics: Albuminuria; Algorithms; Comorbidity; Creatine; Cross-Sectional Studies; Diagnosis, Computer-Assiste | 2013 |
[Medical practice in support of hypertension as risk factor kidney in general medical practice, and primary prevention in children in schools, and the pregnant woman in Annaba (Algeria)].
Topics: Adult; Algeria; Antihypertensive Agents; Biomarkers; Blood Pressure Determination; Child; Creatine; | 2014 |
Serum metabolomic profiling and incident CKD among African Americans.
Topics: Biomarkers; Black or African American; Chromatography, Liquid; Creatine; Cross-Sectional Studies; De | 2014 |
Analysis of correlation between 24-hour urinary sodium and the degree of blood pressure control in patients with chronic kidney disease and non-chronic kidney disease.
Topics: Adult; Aged; Algorithms; Blood Pressure; Creatine; Demography; Female; Humans; Hypertension; Male; M | 2014 |
Urinary sodium excretion has positive correlation with activation of urinary renin angiotensin system and reactive oxygen species in hypertensive chronic kidney disease.
Topics: Adult; Aged; Angiotensinogen; Chemokine CCL2; Creatine; Demography; Female; Follow-Up Studies; Human | 2014 |
Prevalence and variation of Chronic Kidney Disease in the Irish health system: initial findings from the National Kidney Disease Surveillance Programme.
Topics: Adolescent; Adult; Creatine; Demography; Female; Humans; Ireland; Male; Middle Aged; Morbidity; Popu | 2014 |
Presence of early CKD-related metabolic complications predict progression of stage 3 CKD: a case-controlled study.
Topics: Acidosis; Aged; Aged, 80 and over; Anemia; Bicarbonates; Calcium; Case-Control Studies; Creatine; Di | 2014 |
High phosphorus level leads to aortic calcification via β-catenin in chronic kidney disease.
Topics: Actins; Animals; Aorta; beta Catenin; Blood Urea Nitrogen; Calcium; Cells, Cultured; Core Binding Fa | 2015 |
LC-QTOF-MS-based targeted metabolomics of arginine-creatine metabolic pathway-related compounds in plasma: application to identify potential biomarkers in pediatric chronic kidney disease.
Topics: Adolescent; Adult; Arginine; Biomarkers; Child; Child, Preschool; Chromatography, High Pressure Liqu | 2016 |
Predicting Renal Failure Progression in Chronic Kidney Disease Using Integrated Intelligent Fuzzy Expert System.
Topics: Adult; Aged; Artificial Intelligence; Blood Pressure; Calcium; Creatine; Disease Progression; Expert | 2016 |
Prevalence of Chronic Kidney Disease in Korea: the Korean National Health and Nutritional Examination Survey 2011-2013.
Topics: Adult; Aged; Albuminuria; Creatine; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle | 2016 |
HPLC determination of plasma dimethylarginines: method validation and preliminary clinical application.
Topics: Adolescent; Adult; Aged; Arginine; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Cr | 2010 |
Tenofovir-associated proteinuria.
Topics: Adenine; Anti-HIV Agents; Creatine; Female; HIV Infections; Humans; Male; Middle Aged; Organophospho | 2013 |
Elevated urine heparanase levels are associated with proteinuria and decreased renal allograft function.
Topics: Adult; Aged; Aged, 80 and over; Creatine; Female; Glomerular Filtration Rate; Glucuronidase; Humans; | 2012 |
Determinants of arterial stiffness in chronic kidney disease stage 3.
Topics: Age Factors; Aged; Aged, 80 and over; Albuminuria; Blood Pressure; Body Mass Index; Cardiovascular D | 2013 |
Endogenous creatinine clearance. A valuable clinical test of glomerular filtration and a prognostic guide in chronic renal disease.
Topics: Creatine; Creatinine; Humans; Kidney Failure, Chronic; Kidney Function Tests; Prognosis; Renal Insuf | 1962 |
AXON REFLEX SWEATING IN CHRONIC NEPHROPATHY.
Topics: Axons; Blood; Creatine; Creatinine; Humans; Kidney Diseases; Nicotine; Physiology; Reflex; Renal Ins | 1964 |
RETINOPATHIES OF CHRONIC RENAL DISEASE; REVERSALS AFTER RENAL TRANSPLANTATION.
Topics: Arteriosclerosis; Blood Pressure; Blood Urea Nitrogen; Child; Creatine; Creatinine; Glomerulonephrit | 1965 |
How we estimate GFR--a pitfall of using a serum creatinine-based formula.
Topics: Adult; Creatine; Creatinine; Diagnosis, Differential; Dietary Supplements; Glomerular Filtration Rat | 2007 |